Brought to you by 
Chiron refuses $4.5bn Novartis offer, later accepts $5.1bn
27 Sep 2021
Executive Summary
Stating that the offer is "inadequate," Chiron has refused Novartis's proposal to buy the 57.8% of Chiron (112mm fully diluted common shares) it doesn't already own. The offer was $40 cash per share (a 12% premium), for a total of $4.5bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Partial Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiron refuses $4.5bn Novartis offer, later accepts $5.1bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice